A carregar...
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited drug treatment options especially with regard to inotropic therapy. Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myos...
Na minha lista:
| Publicado no: | Drugs Context |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioExcel Publishing Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916097/ https://ncbi.nlm.nih.gov/pubmed/29707029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212518 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|